Site Editor

David S. Ettinger, MD, FACP, FCCP


ASCO 2022: CHRYSALIS-2 Update on Amivantamab-vmjw Plus Lazertinib in NSCLC

By: Lauren Harrison, MD, MS
Posted: Tuesday, June 14, 2022

Combination therapy using the bispecific-antibody amivantamab-vmjw and the third-generation EGFR tyrosine kinase inhibitor lazertinib showed antitumor activity among a cohort of patients with non–small cell lung cancer (NSCLC) that had progressed on standard-of-care treatment. Catherine A. Shu, MD, of Columbia University Medical Center, New York, and colleagues presented results from this population of patients from the CHRYSALIS-2 study at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9006).

This group of 162 patients had EGFR-mutated NSCLC. Patients had been previously treated with osimertinib and platinum-based chemotherapy and experienced disease progression. A subgroup of this population (56 patients) was more heavily pretreated before enrollment. Patients received 1,050 mg of intravenous amivantamab plus 240 mg of oral lazertinib. Both investigators and a blinded independent central review assessed the response to treatment.  

After a median follow-up of 10 months, the overall response rate by blinded review was 33%. One patient achieved a complete response, and 52 patients had a partial response. The clinical benefit rate was 57%, and the median duration of response was 9.6 months. Patients had a median overall survival of 14.8 months. In the heavily pretreated population, the overall response rate was 29%, with 1 complete response and 15 partial responses. The clinical benefit rate for this subgroup was 55%, and the mean duration of response was 8.6 months. In addition, 27 patients in this group had untreated brain metastases, and 26% of these patients experienced complete clearance of their brain lesions after therapy.

The most common adverse events included infusion-related reaction (65%), paronychia (49%), rash (41%), and stomatitis (39%). The most common grade ≥ 3 adverse events were infusion-related reactions (7%), acneiform dermatitis (5%), and hypoalbuminemia (4%). A total of 12% of patients discontinued both amivantamab and lazertinib due to adverse reactions, and 7% discontinued one of the drugs.

Disclosure: For a full list of authors’ disclosures, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.